Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 685 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CROHN'S DISEASE Clear all
Recruiting Phase 2 Interventional

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
64
States / cities
Dothan, Alabama • Mobile, Alabama • Coronado, California + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 11:08 AM EDT
Recruiting No phase listed Observational

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

NCT04846959
View directory record Official record
Conditions
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
Interventions
Risankizumab, Comparator
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Female only
Enrollment
818 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
2
States / cities
Morrisville, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 7, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

NCT02914561
View directory record Official record
Conditions
Crohn's Disease
Interventions
Filgotinib, Placebo
Drug · Other
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
101
States / cities
Dothan, Alabama • Sun City, Arizona • Coronado, California + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 7, 2026, 11:08 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Mayo Clinic IBD Biobank

NCT03756649
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Blood Draw, Urine Collection, Stool Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2065
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 7, 2026, 11:08 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel Disease

NCT05652491
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 20 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 7, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Results available

Vitamin D Supplementation in Crohn's Patients

NCT00742781
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Vitamin D
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Hershey, Pennsylvania • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 7, 2026, 11:08 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study of GSK1605786A

NCT01318993
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786A
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 7, 2026, 11:08 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Family Members at INcreased-risk for Developing Inflammatory Bowel Disease

NCT06655415
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U), Indeterminate Colitis, Crohn's Disease Colon, Crohn's Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis, Ulcerative Proctitis, Ulcerative Proctosigmoiditis
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 7, 2026, 11:08 AM EDT
Recruiting Phase 2 Interventional

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

NCT06918808
View directory record Official record
Conditions
Perianal Fistula Due to Crohn's Disease
Interventions
DB-3Q, Placebo
Biological
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 7, 2026, 11:08 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease

NCT00178438
View directory record Official record
Conditions
Crohn's Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 7, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

NCT01696396
View directory record Official record
Conditions
Crohn's Disease
Interventions
Abrilumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 7, 2026, 11:08 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

NCT01162889
View directory record Official record
Conditions
Healthy
Interventions
Placebo SC Injection, ATR-107 (PF-05230900) SC Injection, ATR-107 (PF-05230900) IV Infusion, Placebo IV Infusion
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 7, 2026, 11:08 AM EDT
Terminated Phase 3 Interventional Results available

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

NCT02240108
View directory record Official record
Conditions
Crohn's Disease
Interventions
Rifaximin EIR, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
78
States / cities
Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 7, 2026, 11:08 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

NCT06986382
View directory record Official record
Conditions
Crohn Disease
Interventions
CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 30 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 7, 2026, 11:08 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With Intracorporeal Anastomosis

NCT04964297
View directory record Official record
Conditions
Crohn's Disease of Large Intestine, Malignant Neoplasm of Colon
Interventions
Obtaining bowel gas samples
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 7, 2026, 11:08 AM EDT
Active, not recruiting No phase listed Observational

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

NCT06249555
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA), Guselkumab (GUS), Mirikizumab (MIR)
Drug
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 7, 2026, 11:08 AM EDT
Completed Phase 2 Interventional

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

NCT05843578
View directory record Official record
Conditions
Fibrostenotic Crohn's Disease
Interventions
AGMB-129, Placebo
Drug
Lead sponsor
Agomab Spain S.L.U.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Hamden, Connecticut • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 7, 2026, 11:08 AM EDT
Recruiting Not applicable Interventional

Impact of Prebiotics in Ulcerative Colitis

NCT06495658
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Prebiotic
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 7, 2026, 11:08 AM EDT
Completed No phase listed Observational

A Long-term Safety Study of Infliximab (Remicade)

NCT00261976
View directory record Official record
Conditions
Arthritis, Rheumatoid, Crohn Disease, Psoriasis
Interventions
Infliximab (Remicade)
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
Not listed
Enrollment
2,971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 7, 2026, 11:08 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078
View directory record Official record
Conditions
Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 7, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

NCT02871635
View directory record Official record
Conditions
Crohn Disease
Interventions
BI 695501, HUMIRA
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Jacksonville, Florida • Kissimmee, Florida • Maitland, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 7, 2026, 11:08 AM EDT
Terminated Not applicable Interventional Results available

Non-invasive Vagus Nerve Stimulation in the Treatment of Crohn's Disease - A Pilot Study

NCT05165108
View directory record Official record
Conditions
Crohn Disease
Interventions
Vagal Nerve Stimulator
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 7, 2026, 11:08 AM EDT
Terminated Phase 2 Interventional

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

NCT05688852
View directory record Official record
Conditions
Crohn Disease
Interventions
VTX958, VTX958 Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Garden Grove, California • Lancaster, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 7, 2026, 11:08 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

NCT03627091
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
73
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 7, 2026, 11:08 AM EDT